2566. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
作者: Anu Osinusi.;Kerry Townsend.;Anita Kohli.;Amy Nelson.;Cassie Seamon.;Eric G Meissner.;Dimitra Bon.;Rachel Silk.;Chloe Gross.;Angie Price.;Mohammad Sajadi.;Sreetha Sidharthan.;Zayani Sims.;Eva Herrmann.;John Hogan.;Gebeyehu Teferi.;Rohit Talwani.;Michael Proschan.;Veronica Jenkins.;David E Kleiner.;Brad J Wood.;G Mani Subramanian.;Phillip S Pang.;John G McHutchison.;Michael A Polis.;Anthony S Fauci.;Henry Masur.;Shyam Kottilil.
来源: JAMA. 2015年313卷12期1232-9页
There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV).
2567. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
作者: Mark S Sulkowski.;Joseph J Eron.;David Wyles.;Roger Trinh.;Jay Lalezari.;Chia Wang.;Jihad Slim.;Laveeza Bhatti.;Joseph Gathe.;Peter J Ruane.;Richard Elion.;Fritz Bredeek.;Robert Brennan.;Gary Blick.;Amit Khatri.;Krystal Gibbons.;Yiran B Hu.;Linda Fredrick.;Gretja Schnell.;Tami Pilot-Matias.;Rakesh Tripathi.;Barbara Da Silva-Tillmann.;Barbara McGovern.;Andrew L Campbell.;Thomas Podsadecki.
来源: JAMA. 2015年313卷12期1223-31页
Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake.
|